President Biden’s Budget Request Includes Much Needed Investment to Combat AMR

IDSA is encouraged that the president’s budget request for FY 2023 includes significant new investment in key infectious diseases priorities to keep our nation healthy.

IDSA Responds to FDA Authorization of Second Booster

FDA’s authorization of a second COVID-19 booster shot for individuals 50 and over provides another opportunity for people to increase their level of protection against severe disease, hospitalization and death. 

IDSA Encouraged by President’s Prioritization of Antimicrobial Resistance

IDSA is heartened by the Administration’s recognition that antimicrobial resistance is a serious and urgent threat to patients and public health.

ID Loan Repayment Advances in Senate PREVENT Pandemics Act

The Senate Health, Education, Labor and Pensions Committee is scheduled on March 15 to mark up the PREVENT Pandemics Act, a package of measures aimed at strengthening our nation’s preparedness for future health emergencies.

IDSA: Florida is Putting Children in Harm’s Way with New Vaccination Policy

The Florida Surgeon General’s decision to recommend against COVID-19 vaccination for healthy children flies in the face of the best medical guidance and only serves to further sow distrust in vaccines that have proven to be the safest, most effective defense against severe COVID-19 disease, hospitalization and death. 

IDSA and HIVMA Oppose Government Interference in Health Care Providers’ Ability to Provide Evidence-based Care

IDSA and HIVMA strongly urge Texas Gov. Greg Abbott to stop government interference in the patient-health care provider relationship by withdrawing the order released last week that classifies medical treatment provided to transgender youth as “child abuse.”

IDSA Support for CDC’s Change to COVID-19 Guidance

The United States has reached an important milestone in ongoing efforts to combat COVID-19. As COVID-19 case rates and hospitalization rates in the United States continue to decline, IDSA supports the U.S. Centers for Disease Control and Prevention’s update to its COVID-19 community guidance.

Ivermectin and COVID-19: Legal Intervention in Clinical Practice Exposes Patients to Serious Harm

Clinicians, scientists and public health leaders on the front lines of our response to the COVID-19 pandemic remain eager for new safe and effective therapies to treat the disease. The suffering and loss of life due to COVID-19 are tragic. We empathize with patients and their loved ones and are working to ensure the best care and outcomes for all.

IDSA Journals Launch Call for Associate Editor Applications

IDSA’s journals, Clinical Infectious Diseases, The Journal of Infectious Diseases and Open Forum Infectious Diseases, are launching a call for applications for all qualified individuals with interest in joining the journals as associate editors.

Infectious Diseases Society of America Announces Next Editor-in-Chief of Clinical Infectious Diseases

IDSA is pleased to announce that Paul E. Sax, MD, FIDSA, has been selected as the next editor-in-chief of Clinical Infectious Diseases. Dr. Sax will succeed Robert T. Schooley, MD, on July 1, 2022, following Dr. Schooley’s years of outstanding service to the journal and the Society.

IDSA Converts IDA&E Task Force to New Committee to Continue Inclusion, Diversity, Access and Equity Focus

In recognition of the importance of inclusion, diversity, access and equity as long-term priorities and core values for IDSA, the Society’s Board of Directors recently approved the creation of a permanent IDA&E Committee.

More than $1.7 Million in IDSA Foundation Grant Funds Attracts Diverse Minds to Alzheimer’s Research

The grant funds, which were awarded through the Foundation’s Microbial Pathogenesis in Alzheimer’s Disease Grant program, were dispersed among 11 researchers representing a wide range of research fields and institutions across the U.S.